Role of Surgery in Ovarian Cancer: An Update

References

• Annual report on the results of treatment in gynaecological cancer, vol 23, Statements of results obtained in patients treated in, 1990–1992. J Epidemiol Biostat, 1998, 3: 1–135.
   Google Scholar
• Dembo A., Davy M., Stenwig A. E., Berle E. J., Bush R. S., KJ0RSTAD K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol, 1990, 75: 263–173.
   Google Scholar
• Sevelda P., Vavra N., Schemper M., Salzer H. Prognostic factors for survival in stage I epithelial ovarian carcinoma. Cancer, 1990, 65: 2349–2352.
   Google Scholar
• Young R. C., Walton L. A., Ellenberg S. S. et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomised trials. N Engl J Med, 1990, 322: 1021–1027.
   Google Scholar
• Finn C., Luesley D., Buxton E. et al. Is stage I epithelial ovarian cancer overtreated both surgically and systematically ? Results of a five-year cancer registry review. Br J Obstet Gynaecol, 1992, 99: 54–58.
   Google Scholar
• Vergote I. B., Kaern, Abeler V. M., Pettersen E. O., De Vos L. N., Trope C. G. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and desoxyribonucleic acid ploidy in predictin relapse. Am J Obstet Gynecol, 1993, 169: 40–52.
   Google Scholar
• Bertelsen K., H0lund B., Andersen J. E., Nielsen K., Str0Yer I., Ladehoff P. Prognostic factors and adjuvant treatment in early ovarian epithelial cancer. Int J Gynecol Cancer, 1993, 3: 211218.
   Google Scholar
• Sjövall K., Nilsson B., Einhorn N. Different types of rupture of the tumor capsule and the impact on survival in early ovarian carcinoma. Int J Gynecol Cancer, 1994, 4: 333–336.
   Google Scholar
• Ahmed F. Y., Wiltshaw E., A’Hern B. et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol, 1996, 14: 2968–2975.
   Google Scholar
• Tropé C., Kaern J., Högberg T. et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol, 2000, 11: 281–288.
   Google Scholar
• Vergote I., De Brabanter J., Fyles A., Bertelsen K., Einhorn N., Sevelda P., Gore M., Kaern J., Verrelst H., Sjövall K., Timmerman D., Vandewalle J., Van Gramberen M., Tropé C. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. The Lancet, 2001, 357: 176–182.
   Google Scholar
• Kodama S., Tanaka K., Tokunaga A., Sudo N., Takahashi T., Matsui K. Multivariate analysis of prognostic factors in patients with ovarian cancer stage I and II. Int J Gynaecol Obstet, 1997, 56: 147–153.
   Google Scholar
• Webb M. J., Decker D. G., Mussey E., Williams T. J. Factors influencing survival in stage I ovarian cancer. Am J Obstet Gynecol, 1973, 116: 222–228.
   Google Scholar
• Sainz De La Cuesta R., Goff B. A., Fuller A. F., Nikrui N., Eichhorn J. H., Rice L. W. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol, 1994, 84: 1–7.
   Google Scholar
• Berek J. S. Ovarian cancer spread: is laparoscopy to blame ? Lancet, 1995, 346: 200.
   Google Scholar
• Trimbos J. B., Hacker N. F. The case against aspirating ovarian cysts. Cancer, 1993, 72: 828–831.
   Google Scholar
• Maiman M., Seltzer V., Boyce J. Laparoscopic excision of ovarian neoplasms subsequently found to be malignant. Obstet Gynecol, 1991, 77: 563–565.
   Google Scholar
• Kindermann G., Maassen V., Kuhn W. Laparoskopisches “Anoperieren” von ovariellen Malignomen: Erfahrungen aus 127 Deutschen Frauenkliniken. Geburtshilfe Frouwenheilkd, 1995, 55: 687–694.
   Google Scholar
• Leminen A., Lehtovirta P. Spread of ovarian cancer after laparo-scopic surgery: report of eight cases. Gynecol Oncol, 1999, 75: 387–390.
   Google Scholar
• Lehner R., Wenzl R., Heinzl H., Husslein P., Sevelda P. Influence of delayed staging laparotomy after laparoscopic removal of ovarian masses later found malignant. Obstet Gynecol, 1998, 92: 967–971.
   Google Scholar
• Young R. C., Decker D. G., Wharton J. T., Piver M. S., Sindelar W. F., Edwards B. K., Smith J. P. Staging laparotomy in early ovarian cancer. JAMA, 1983, 250 (22): 1097–1101
   Google Scholar
• Zanetta G., Rota S., Chiari S., Bonazzi C., Bratina G., Torri V., Mangioni C. The accuracy of staging: an important prognostic determinator in stage i ovarian carcinoma. A multivariate analysis. Ann Oncol, 1998, 9 (10): 1097–101
   Google Scholar
• Trimbos J. B., Vergote I., Bolis G., Vermorken J. B., Mangioni C., Madroñal C., Franchi M., Tateo S., Zanetta G., Scarfone G., Giurgea L., Timmers P., Coens C., Pecorelli S. impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst, 2003, 95 (2): 113–125.
   Google Scholar
• Bel J., Brady M., Lage J., Walker J., Look K., Rose E., Spirtos N., Young R. C. Proceedings, 34th meeting of the Society of Gynaecologic Oncology, New Oreleans, 31-01-2003-04-022003, 70, Abstract 1.
   Google Scholar
• Trimbos J. B., Parmar M., Vergote I., Guthrie D., Bolis G., Colombo N., Vermorken J. B., Torri V., Mangioni C., Pecorelli S., Lissoni A., Swart A. M. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In ovarian Neoplasm trial: two parallel randomized phase iii trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst, 2003, 95 (2): 105–112.
   Google Scholar
• Berek J. S., Tropé C., Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol, 199, 10 (Suppl 1): S3–S7.
   Google Scholar
• Aure J. C., Hoeg K., Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up op 990 cases. Obstet Gynecol, 1971, 37: 1–9.
   Google Scholar
• Griffiths C. T., Fuller A. F. Intensive surgical and chemothera-peutic management of advanced ovarian cancer. Surg Clin North Am, 1978, 58: 131–142.
   Google Scholar
• Berek J. S., Tropé C., Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Annals of Oncology, 10 (Suppl. 1): S3-S7, 1999.
   Google Scholar
• Smith J. P., Day T. G. Jr. Review of ovarian cancer at the University of Texas Systems Cancer Center, MD Anderson Hospital and Tumor Institute. Am J Obstet Gynecol, 1979, 135: 984–993.
   Google Scholar
• Bertelsen K., Jacobsen A., Andersen J. E. et al. A randomized study of cyclophosphamide and cisplatinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol, 1987, 28: 161–169.
   Google Scholar
• Gruppo Interegionale Cooperativo Oncologico Ginecologia. Randomised comparison of cisplatin with cyclophosphamide/dox-orubicin/cisplatin in advanced ovarian cancer. Lancet, 1987, 2 (8555): 353–359.
   Google Scholar
• Voest E. E., Van Houwelingen J. C., Neijt J. P. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives. Eur J Cancer Clin Oncol, 1989, 25: 711–720.
   Google Scholar
• Hunter R. W., Alexander N. D., Soutter W. P. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreduc-tive surgery an independent determinant of prognosis ? Am J Obstet Gynecol, 1992, 166: 504–511.
   Google Scholar
• Bristow R. E., Tomacruz R. S., Armstrong D. K. et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 2002, 20 (5): 1248–1259.
   Google Scholar
• Heintz A. P., Hacker N. F., Berek J. S. et al. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol, 1986, 67: 783–788.
   Google Scholar
• Potter M. E., Patridge E. E., Hatch K. D. et al. Primary surgical therapy of ovarian cancer: how much and when ? Gynecol Oncol, 1991, 140:, 195–200.
   Google Scholar
• Redman J. R., Petroni G. R., Saigo P. E. et al. Prognostic factors in advanced ovarian carcinoma. J Clin Oncol, 1986, 4: 515–523.
   Google Scholar
• Neijt J. P., Ten Bokkel Huinink W. W., Van Der Burg M. E. Randomised trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma. J Clin Oncol, 1987, 5: 1157–1168.
   Google Scholar
• Hacker N. F., Berek J. S., Lagasse L. D. et al. Primary cytore-ductive surgery for epithelial ovarian cancer. Obstet Gynecol, 1983, 61: 413–420.
   Google Scholar
• Heintz A. P., Van Oosterom A. T., Trimbos J. B. et al. The treatment of advanced ovarian carcinoma (i): clinical variables associated with prognosis. Gynecol Oncol, 1988, 30: 347–358.
   Google Scholar
• Hoskins W. J., Bundy B. N., Thigpen J. T. et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol, 1992, 47: 159–166.
   Google Scholar
• Vergote I., De Wever I., Tjalma W. et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol, 1998, 71: 431–436.
   Google Scholar
• Eisenkop S. M., Spirtos N. M. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer ? Gynecol Oncol, 2001, 82 (3): 489–497.
   Google Scholar
• Burghardt E., Giardi F., Lahousen M. et al. Patterns of pelvic paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol, 1991, 40: 103–106.
   Google Scholar
• Friedlander M. L., Hedley D. W., Swanson C. et al. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol, 1988, 6: 282–290.
   Google Scholar
• Farias-Eisner R., Teng F., Oliveira M. et al. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage iii ovarian cancer after optimal primary cytoreduc-tive surgery. Gynecol Oncol, 1944, 55: 108–110.
   Google Scholar
• Eisenkop S. M., Nalick R. H., Wang H. et al. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol, 1993, 51: 224–229.
   Google Scholar
• Van Dam P. A., Tjalma W., Weyler J. et al. Ultraradical debulk-ing of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomised study. Am J Obstet Gynecol, 1996, 174: 943–950.
   Google Scholar
• Berek J. S., Bertelsen A., Du Bois A. et al. Advanced epithelial ovarian cancer:, 1998 consensus statements. Annals of Oncology, 1999, 10 (Suppl 1): S87–S92.
   Google Scholar
• Van Der Burg M. E., Van Lent M., Buyse M. et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med, 1955, 332: 629–634.
   Google Scholar
• Rose P. G., Nerenstone S., Brady M. et al. A phase III randomised study of interval secondary cytoreducion in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proceedings of ASCO, 2002, Volume 21: Abstract 802: 201a.
   Google Scholar
• Lawton F. G., Redman C. W., Luesley D. M. et al. Neoadjuvant (cytoreductive ) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol, 1989, 73: 61–65.
   Google Scholar
• Jacob J. H., Gershenson D. M., Morris M. et al. Neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer. Gynecol Oncol, 1991, 42: 146–150.
   Google Scholar
• Lim J. T., Green J. A. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol (R Coll Radiol), 1993, 5: 198–202.
   Google Scholar
• Shimizu Y., Hasumi K. Treatment of stage III and IV ovarian cancer-is neoadjuvant chemotherapy effective ? Nippon Sanka Fujinka Gakkai Zasshi, 1993, 45: 1007–1014.
   Google Scholar
• Onnis A., Marchetti M., Padovan P. et al. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynecol Oncol, 1996, 17: 393–396.
   Google Scholar
• Surwit E., Childers J., Atlas I. et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynaecol Cancer, 1996, 6: 356–361.
   Google Scholar
• Schwartz P. E., Rutherfort T J., Chamberst J. T. et al. Neo-adjuvant chemotherapy for advanced ovarian cancer: long term survival. Gynecol Oncol, 1999, 72: 93–99.
   Google Scholar
• Ansquer Y., Leblanc E., Clough K. et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer, 2001, 91 (12): 2329–2334.
   Google Scholar
• Kuhn W., Rutke S., Spathe K. et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in international Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer, 2001, 92 (10): 2585–2591.
   Google Scholar
• Recchi F., De Filippis S., Rosselli M. et al. Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. Eur J Gynaecol Oncol, 2001, 22 (4): 287–291.
   Google Scholar
• Kayikcioglu F., Kose M. F., Boran N. et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian cancer. Int J Gynecol Cancer, 2001, 11 (6): 466–470.
   Google Scholar
• Ushijima K., Ota S., Komai K. et al. Clinical assessment of neo-adjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. Int-Surg, 2002, 87 (3): 185–190.
   Google Scholar
• Fanfani F., Ferrandina G., Corrado G. et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO Stage IlIc ovarian cancer patients. Oncology, 2003, 65 (4): 316–322.
   Google Scholar
• Shibata K., Kikkawa F., Mika M. et al. Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: survival benefit and prognostic factors. Int J Gynecol Cancer, 2003, 13 (5): 587592.
   Google Scholar
• Morice P., Dubernard G., Rey et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg, 2003, 197 (6): 955–963.
   Google Scholar
• Mazzeo F., Berliere M., Kerger et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced stage ovarian cancer. Gynecol Oncol, 2003, 90 (1): 163–169.
   Google Scholar
• Vrscaj M. U., Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case control study. Eur J Gynaecol Oncol, 2002, 23 (5): 405–410.
   Google Scholar
• Nelson B. E., Rosenfeld A. T., Schwartz P. E. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol, 1993, 11: 166–172.
   Google Scholar
• Grijspeerdt S., Clabout L., Van Hoe L. et al. Intraperitoneal contrast material combined with CT for detection of peritoneal metastases in ovarian cancer. Eur J Gynaecol Oncol, 1998, 19 (5): 434437.
   Google Scholar
• Berek J. S., Hacker N. F., Lagasse L. D. et al. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol, 1983, 61: 189–93.
   Google Scholar
• Janicke F., Hoscher M., Kuhn W. et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer, 1992, 70: 2129–2136.
   Google Scholar
• Munkarah A. R., Levenback C., Wolf J. K., Bodurka-Bevers D., Tortolero-Luna G., Morris R. T., Gershenson D. M. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial cancer. Gynecol Oncol, 2001, 81 (2): 237–241.
   Google Scholar
• Segna R. A., Dottino P. R., Mandeli J. P. et al. Secondary cytore-duction for ovarian cancer following cisplatin therapy. J Clin Oncol, 1993, 11: 434–439.
   Google Scholar
• Morris M., Gershenson D. M., Taylor Wharton J. et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol, 1989, 34: 334–338.
   Google Scholar
• Pecorelli S., Sartori E., Santin A. D. Follow up after primary therapy: Management of the symptomatic patient-Surgery. Gynecol Oncol, 1994, 55 S: 138–142.
   Google Scholar
• Meier W., Romisch M., Hepp H. Stellenwert der Rezidivchirurgie in der Behandlung des ovarialkarzinoms. Geburtsh U Frauenhlk, 1993, 53: 30–34.
   Google Scholar
• Tay E. H., Grant P. T., Gebski V., Hacker N. F. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol, 2002, 99 (6): 1008–1013.
   Google Scholar
• Zang R. Y., Zhang Z. Y., Li Z. T., Chai S. M., Tang M. Q., Chen J., Liu Q. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Eur J Surg Oncol, 2000, 26 (8): 798–804.
   Google Scholar
• Scarabelli C., Gallo A., Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol, 2001, 83 (3): 504–512.
   Google Scholar
• Eisenkop S. M., Friedman R. L., Spiritos N. M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer, 2000, 88 (1): 144–153.
   Google Scholar
• Burke J. W., Morris M. Secondary cytoreductive operations pp. 301–312. In: Rubin R. C., Sutton G. P. (eds.). Ovarian Cancer McGraw-Hill, New York, 1993.
   Google Scholar
• Bais J. J. M., Ansinck A. C., Schilthuis M. S. Intestinal obstruction in advanced ovarian cancer. In: Ledermann J. A., Hoskins W. J., Kaye S. B., Vergote I. (eds.). Clinical management of ovarian cancer. Martin Dunitz, Ltd, London-, 2001: 165–178.
   Google Scholar
• D’Agostino G., Amant F., Berteloot P., Scambia G., Vergote I. Phase ii study of gemcitabine in recurrent platinum-and pacli-taxel-resistant ovarian cancer. Gyn Oncol, 2003, 88: 266–269.
   Google Scholar
• Malone J. J., Koonce T., Larson D. M. et al. Palliation of small bowel obstruction by percutaneous gastrostomy in patients with progressive ovarian carcinoma. Obstet Gynecol, 1985, 65: 56872.
   Google Scholar
• Baines M., Oliver D. J., Carter R. L. Medical management of intestinal obstruction in patients with advanced malignant disease. Lancet, 1985, 2: 990–3.
   Google Scholar